From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease
- PMID: 25949527
- PMCID: PMC4416294
- DOI: 10.1177/1756283X15576462
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease
Abstract
Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.
Keywords: Crohn’s Disease; Inflammatory Bowel Disease; anti-TNF; biologics.
Conflict of interest statement
References
-
- Ananthakrishnan A., Hur C., Korzenik R. (2012) Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn’s disease: results of a decision analysis. Dig Dis Sci 57: 472–480. - PubMed
-
- Ardizzone S., Puttini P., Cassinotti A., Porro G. (2008) Extraintestinal manifestations of inflammatory bowel disease. Digest Liver Dis 40: 253–259. - PubMed
-
- Aufses A., Jr. (2001) The history of Crohn’s disease. Surg Clin N Am 81: 1–11. - PubMed
-
- Bandzar S., Gupta S., Platt M. (2013) Crohn’s disease: a review of treatment options and current research. Cell Immunol 286: 45–52. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
